Venous thromboembolism (VTE) is a major complication of cancer that occurs in 4–20% of patients with cancer.¹ The incidence of VTE in patients with cancer is 4–7-times higher than in patients without cancer.^2,3 VTE not only prolongs the hospitalization time of patients but is also related to higher medical expenses.^4,5 Furthermore, it complicates the clinical management of cancer and may terminate or delay the required anticancer treatment.⁶ The survival rate in patients with cancer with VTE is only one-third of that in other patients with cancer.⁷

中文翻译：

---

癌症患者血栓预防的有效性和安全性：系统评价和荟萃分析

静脉血栓栓塞 (VTE) 是癌症的主要并发症，4-20% 的癌症患者会发生这种情况。¹癌症患者 VTE 的发生率比非癌症患者高 4-7 倍。^2,3 VTE不仅延长了患者的住院时间，还与较高的医疗费用有关。^4,5此外，它使癌症的临床管理变得复杂，并可能终止或延迟所需的抗癌治疗。⁶患有 VTE 的癌症患者的生存率仅为其他癌症患者的三分之一。⁷